Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report sent to investors on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Trading Up 0.2 %

Cara Therapeutics stock opened at $0.26 on Friday. The firm’s fifty day moving average price is $0.29 and its two-hundred day moving average price is $0.33. The firm has a market capitalization of $14.37 million, a price-to-earnings ratio of -0.15 and a beta of 0.64. Cara Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.31.

Institutional Trading of Cara Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Disciplined Growth Investors Inc. MN grew its holdings in Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 120,660 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Cara Therapeutics in the 3rd quarter worth $29,000. Finally, FMR LLC lifted its position in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares in the last quarter. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.